DOCSLIB.ORG

Domains and Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Domains and Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design viruses Review Domains and Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design Xuhua Xia 1,2 1 Department of Biology, University of Ottawa, Marie-Curie Private, Ottawa, ON K1N 9A7, Canada; [email protected]; Tel.: +1-613-562-5718 2 Ottawa Institute of Systems Biology, University of Ottawa, Ottawa, ON K1H 8M5, Canada Abstract: The spike protein in SARS-CoV-2 (SARS-2-S) interacts with the human ACE2 receptor to gain entry into a cell to initiate infection. Both Pfizer/BioNTech’s BNT162b2 and Moderna’s mRNA-1273 vaccine candidates are based on stabilized mRNA encoding prefusion SARS-2-S that can be produced after the mRNA is delivered into the human cell and translated. SARS-2-S is cleaved into S1 and S2 subunits, with S1 serving the function of receptor-binding and S2 serving the function of membrane fusion. Here, I dissect in detail the various domains of SARS-2-S and their functions discovered through a variety of different experimental and theoretical approaches to build a foundation for a comprehensive mechanistic understanding of how SARS-2-S works to achieve its function of mediating cell entry and subsequent cell-to-cell transmission. The integration of structure and function of SARS-2-S in this review should enhance our understanding of the dynamic processes involving receptor binding, multiple cleavage events, membrane fusion, viral entry, as well as the emergence of new viral variants. I highlighted the relevance of structural domains and dynamics to vaccine development, and discussed reasons for the spike protein to be frequently featured in the conspiracy theory claiming that SARS-CoV-2 is artificially created. Keywords: COVID-19; spike protein; S-2P; SARS-CoV-2; cleavage; vaccine; protein structure; Citation: Xia, X. Domains and hydrophobicity; isoelectric point Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design. Viruses 2021, 13, 109. https://doi.org/10.3390/v13010109 1. Introduction Academic Editors: SARS-CoV-2 uses its trimeric spike protein for binding to host angiotensin-converting Kenneth Lundstrom and Alaa. A. enzyme 2 (ACE2) and for fusing with cell membrane to gain cell entry [1–4]. This is a A. Aljabali multi-step process involving three separate S protein cleavage events to prime the SARS-2-S Received: 15 December 2020 for interaction with ACE2 [2,3], and subsequent membrane fusion and cell entry. These Accepted: 12 January 2021 processes involve different domains of the S protein interacting with host cell and other Published: 14 January 2021 intracellular and extracellular components. Efficiency in each step could contribute to virulence and infectivity. Disrupting any of these steps could lead to medical cure. Publisher’s Note: MDPI stays neu- The domain structure is very similar between SARS-S (UniProtKB: P59594) and SARS- tral with regard to jurisdictional clai- 2-S (UniprotKB: P0DTC2). Both are cleaved to generate S1 and S2 subunits at specific ms in published maps and institutio- cleavage sites (Figure1A). S1 serves the function of receptor-binding and contains a signal nal affiliations. peptide (SP) at the N terminus, an N-terminal domain (NTD), and receptor-binding domain (RBD). S2 (Figure1A) functions in membrane fusion to facilitate cell entry, and it contains a fusion peptide (FP) domain, internal fusion peptide (IFP), two heptad-repeat domains (HR1 Copyright: © 2021 by the author. Li- and HR2), transmembrane domain, and a C-terminal domain [2,3,5–8]. However, there are censee MDPI, Basel, Switzerland. also significant differences between SARS-S and SARS-2-S. For example, the contact amino This article is an open access article acid sites between SARS-S and human ACE2 (hACE2) [5,7,9,10] differ from those between distributed under the terms and con- SARS-2-S and hACE2 [11–14]. This may explain why some antibodies that are effective ditions of the Creative Commons At- against SARS-S are not effective against SARS-2-S [4], especially those developed to target tribution (CC BY) license (https:// the ACE2 binding site of SARS-S [15]. In this article, numerous experiments on SARS-S are creativecommons.org/licenses/by/ considered to facilitate comparisons and to highlight differences between the two. 4.0/). Viruses 2021, 13, 109. https://doi.org/10.3390/v13010109 https://www.mdpi.com/journal/viruses Viruses 2021, 13, x FOR PEER REVIEW 2 of 17 Viruses 2021, 13, 109 2 of 16 (http://creativecommons.org/licenses experiments on SARS-S are considered to facilitate comparisons and to highlight differ- /by/4.0/). ences between the two. (A) S1: 14-667 S2: 668-1255 14-685 686-1273 (site 1) 697-1273 (site 2) NTD:14-290 RBD: 306-527 S2': 798-1255 FP CT IFP TM HR2 SP 14-303 319-541 HR1 816-1273 (B) 770-788 873-888 524CVNFNFN530 788-806 1145-1184 1196-1216 MFIFLLFLTLTSG 696 site2: cleavage 891-906 ||||||| 1163-1202 1214-1234 || || | | | 685 site1: cleavage 538CVNFNFN544 MFVFLVLLPLVSS SARS-S SARS-2-S (D) 287KCSVKSFEIDKGIYQTSNFRVVP309 3 815 site cleavage 924-972 942-990 2.4 ||: ||| :||||||||||| | STALGKL ASALGKL g 300KCTLKSFTVEKGIYQTSNFRVQP322 QDVVNQN QDVVNQN c d AQALNTL AQALNTL 1.9 (C) | f a 697 VKQLSSN VKQLSSN | b e 686 FGAISSV FGAISSV LNDILSR LNDILSR 1.4 | (E) 816 LDKVEAE LDKVEAE 0.9 0.4 Hydrophobicity -0.1 -0.6 -1.1 -1.6 1 201 401 601 801 1001 1201 (F) Window start Figure 1. Domain structure of SARS-S and SARS-2-S. (A) Key domains in SARS-S and SARS-2-S. FigureSP, signal 1.peptide;Domain NTD, N structure-terminal domain; of SARS-S RBD, receptor and-binding SARS-2-S. domain; (A FP,) Keyfusion domains peptide; in SARS-S and SARS-2-S. SP, signalIFP, internal peptide; fusion peptide; NTD, HR,N heptad-terminal repeats; domain; TM, transmembrane RBD, receptor-bindingdomain; CT, cytoplasmic domain; FP, fusion peptide; IFP, tail. The top and bottom numbers in each domain pertain to SARS-S and SARS-2-S, respectively. internalThe red arrows fusion indicate peptide; cleavage sites HR,, and heptad their numbers repeats; pertain TM, to SARS transmembrane-2-S; (B) Alignment domain; of CT, cytoplasmic tail. The topSP between and bottomSARS-S (top) numbers and SARS-2 in-S (bottom) each domain; (C,D) Alignment pertain of two to inter SARS-S-domain andsegments SARS-2-S,; respectively. The red (E) HR1 in SARS-S and SARS-2-S, together with the top view of a helix showing hydrophobic posi- arrowstions a and indicate d on the same cleavage side; (F) Hydrophobicity sites, and their plot generated numbers from pertain DAMBE [16]. to SARS-2-S; (B) Alignment of SP between SARS-S (top) and SARS-2-S (bottom); (C,D) Alignment of two inter-domain segments; (E) HR1 in 2. General Features of SARS-S and SARS-2S SARS-SSARS and-2-S is SARS-2-S, 1273 aa long together, in contrast with to 1255 the aa top in viewSARS-S. of Individual a helix showing protein do- hydrophobic positions a and d onmains the in samethe S protein side; (tendF) Hydrophobicity to fold independently plot and generated are associated from with DAMBE specific func- [16]. tions. The numbers (Figure 1A) that indicate the start/end of individual domains in SARS- S and SARS-2-S may mislead readers to think that the boundary is based on some clearly 2.recognizable General physiochemical Features oflandmarks. SARS-S In fact, and these SARS-2S numbers are for rough reference only. For example, the boundaries of RBD in SARS-S mainly result from experiments with differentSARS-2-S RNA clones is containing 1273 aa different long, inparts contrast of RBD [17 to–19]. 1255 The aa 5′ side in SARS-S. is delimited Individual protein domains inby the the site S where protein upstream tend mutations/deletions to fold independently do not affect receptor and binding are associated, but down- with specific functions. stream mutations/deletions do affect receptor binding. Similarly, the 3′ side is where up- Thestream numbers mutations/deletions (Figure affec1A)t receptor that binding indicate, but downstream the start/end mutations/deletions of individual domains in SARS-S anddo notSARS-2-S have an effect.may Boundaries mislead of some readers domains are to substantiated think that bythe protein boundary structure, is based on some clearly recognizablefor example, the boundaries physiochemical of RBD [11–14,20], landmarks. but some are Innot fact,substantiated these by numbers protein are for rough reference structure. only.Some For inter example,-domain segments the boundaries(Figure 1C,D) could of RBDbe much in more SARS-S conserved mainly than result from experiments withneighboring different domains. RNA For example, clones C822, containing D830, L831, and different C833 in SARS parts-S (correspond- of RBD [17–19]. The 50 side is de- limiteding to C840, by D848, the L849 site, and where C851 in upstream SARS-2-S) are mutations/deletions located between FP and IFP but do are not affect receptor binding, highly conserved and critically important for membrane fusion [21]. Similarly, V601 in 0 butSARS- downstreamS (corresponding to mutations/deletions V615 in SARS-2-S) does not belong do affect to any recognized receptor domain binding. Similarly, the 3 side is(Figure where 1A) but upstream is highly conserved. mutations/deletions Replacing it by G contributes affect receptor to viral escape binding, from but downstream muta- tions/deletions do not have an effect. Boundaries of some domains are substantiated by protein structure, for example, the boundaries of RBD [11–14,20], but some are not substantiated by protein structure. Some inter-domain segments (Figure1C,D) could be much more conserved than neighboring domains.
Load more

Recommended publications
  • PARSANA-DISSERTATION-2020.Pdf
    DECIPHERING TRANSCRIPTIONAL PATTERNS OF GENE REGULATION: A COMPUTATIONAL APPROACH by Princy Parsana A dissertation submitted to The Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland July, 2020 © 2020 Princy Parsana All rights reserved Abstract With rapid advancements in sequencing technology, we now have the ability to sequence the entire human genome, and to quantify expression of tens of thousands of genes from hundreds of individuals. This provides an extraordinary opportunity to learn phenotype relevant genomic patterns that can improve our understanding of molecular and cellular processes underlying a trait. The high dimensional nature of genomic data presents a range of computational and statistical challenges. This dissertation presents a compilation of projects that were driven by the motivation to efficiently capture gene regulatory patterns in the human transcriptome, while addressing statistical and computational challenges that accompany this data. We attempt to address two major difficulties in this domain: a) artifacts and noise in transcriptomic data, andb) limited statistical power. First, we present our work on investigating the effect of artifactual variation in gene expression data and its impact on trans-eQTL discovery. Here we performed an in-depth analysis of diverse pre-recorded covariates and latent confounders to understand their contribution to heterogeneity in gene expression measurements. Next, we discovered 673 trans-eQTLs across 16 human tissues using v6 data from the Genotype Tissue Expression (GTEx) project. Finally, we characterized two trait-associated trans-eQTLs; one in Skeletal Muscle and another in Thyroid. Second, we present a principal component based residualization method to correct gene expression measurements prior to reconstruction of co-expression networks.
    [Show full text]
  • Protein Structure & Folding
    6 Protein Structure & Folding To understand protein folding In the last chapter we learned that proteins are composed of amino acids Goal as a chemical equilibrium. linked together by peptide bonds. We also learned that the twenty amino acids display a wide range of chemical properties. In this chapter we will see Objectives that how a protein folds is determined by its amino acid sequence and that the three-dimensional shape of a folded protein determines its function by After this chapter, you should be able to: the way it positions these amino acids. Finally, we will see that proteins fold • describe the four levels of protein because doing so minimizes Gibbs free energy and that this minimization structure and the thermodynamic involves both making the most favorable bonds and maximizing disorder. forces that stabilize them. • explain how entropy (S) and enthalpy Proteins exhibit four levels of structure (H) contribute to Gibbs free energy. • use the equation ΔG = ΔH – TΔS The structure of proteins can be broken down into four levels of to determine the dependence of organization. The first is primary structure, the linear sequence of amino the favorability of a reaction on acids in the polypeptide chain. By convention, the primary sequence is temperature. written in order from the amino acid at the N-terminus (by convention • explain the hydrophobic effect and its usually on the left) to the amino acid at the C-terminus. The second level role in protein folding. of protein structure, secondary structure, is the local conformation adopted by stretches of contiguous amino acids.
    [Show full text]
  • Evolution of Biomolecular Structure Class II Trna-Synthetases and Trna
    University of Illinois at Urbana-Champaign Luthey-Schulten Group Theoretical and Computational Biophysics Group Evolution of Biomolecular Structure Class II tRNA-Synthetases and tRNA MultiSeq Developers: Prof. Zan Luthey-Schulten Elijah Roberts Patrick O’Donoghue John Eargle Anurag Sethi Dan Wright Brijeet Dhaliwal September 25, 2006. A current version of this tutorial is available at http://www.scs.uiuc.edu/˜schulten/tutorials/evolution/ CONTENTS 2 Contents 1 Introduction 4 1.1 The MultiSeq Bioinformatic Analysis Environment . 4 1.2 Aminoacyl-tRNA Synthetases: Role in translation . 4 1.3 Getting Started . 7 1.3.1 Requirements . 7 1.3.2 Copying the tutorial files . 7 1.3.3 Configuring MultiSeq . 7 1.3.4 Configuring BLAST for MultiSeq . 10 1.4 The Aspartyl-tRNA Synthetase/tRNA Complex . 12 1.4.1 Loading the structure into MultiSeq . 12 1.4.2 Selecting and highlighting residues . 13 1.4.3 Domain organization of the synthetase . 14 1.4.4 Nearest neighbor contacts . 14 2 Evolutionary Analysis of AARS Structures 17 2.1 Loading Molecules . 17 2.2 Multiple Structure Alignments . 18 2.3 Structural Conservation Measure: Qres . 19 2.4 Structure Based Phylogenetic Analysis . 21 2.4.1 Limitations of sequence data . 21 2.4.2 Structural metrics look further back in time . 23 3 Complete Evolutionary Profile of AspRS 26 3.1 BLASTing Sequence Databases . 26 3.1.1 Importing the archaeal sequences . 26 3.1.2 Now the other domains of life . 27 3.2 Organizing Your Data . 28 3.3 Finding a Structural Domain in a Sequence . 29 3.4 Aligning to a Structural Profile using ClustalW .
    [Show full text]
  • DNA Glycosylase Exercise - Levels 1 & 2: Answer Key
    Name________________________ StarBiochem DNA Glycosylase Exercise - Levels 1 & 2: Answer Key Background In this exercise, you will explore the structure of a DNA repair protein found in most species, including bacteria. DNA repair proteins move along DNA strands, checking for mistakes or damage. DNA glycosylases, a specific type of DNA repair protein, recognize DNA bases that have been chemically altered and remove them, leaving a site in the DNA without a base. Other proteins then come along to fill in the missing DNA base. Learning objectives We will explore the relationship between a protein’s structure and its function in a human DNA glycosylase called human 8-oxoguanine glycosylase (hOGG1). Getting started We will begin this exercise by exploring the structure of hOGG1 using a molecular 3-D viewer called StarBiochem. In this particular structure, the repair protein is bound to a segment of DNA that has been damaged. We will first focus on the structure hOGG1 and then on how this protein interacts with DNA to repair a damaged DNA base. • To begin using StarBiochem, please navigate to: http://mit.edu/star/biochem/. • Click on the Start button Click on the Start button for StarBiochem. • Click Trust when a prompt appears asking if you trust the certificate. • In the top menu, click on Samples à Select from Samples. Within the Amino Acid/Proteins à Protein tab, select “DNA glycosylase hOGG1 w/ DNA – H. sapiens (1EBM)”. “1EBM” is the four character unique ID for this structure. Take a moment to look at the structure from various angles by rotating and zooming on the structure.
    [Show full text]
  • The Architecture of the Protein Domain Universe
    The architecture of the protein domain universe Nikolay V. Dokholyan Department of Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, NC 27599 ABSTRACT Understanding the design of the universe of protein structures may provide insights into protein evolution. We study the architecture of the protein domain universe, which has been found to poses peculiar scale-free properties (Dokholyan et al., Proc. Natl. Acad. Sci. USA 99: 14132-14136 (2002)). We examine the origin of these scale-free properties of the graph of protein domain structures (PDUG) and determine that that the PDUG is not modular, i.e. it does not consist of modules with uniform properties. Instead, we find the PDUG to be self-similar at all scales. We further characterize the PDUG architecture by studying the properties of the hub nodes that are responsible for the scale-free connectivity of the PDUG. We introduce a measure of the betweenness centrality of protein domains in the PDUG and find a power-law distribution of the betweenness centrality values. The scale-free distribution of hubs in the protein universe suggests that a set of specific statistical mechanics models, such as the self-organized criticality model, can potentially identify the principal driving forces of molecular evolution. We also find a gatekeeper protein domain, removal of which partitions the largest cluster into two large sub- clusters. We suggest that the loss of such gatekeeper protein domains in the course of evolution is responsible for the creation of new fold families. INTRODUCTION The principles of molecular evolution remain elusive despite fundamental breakthroughs on the theoretical front 1-5 and a growing amount of genomic and proteomic data, over 23,000 solved protein structures 6 and protein functional annotations 7-9.
    [Show full text]
  • Common COVID-19 Myths and Misinformation
    Common COVID-19 Myths and Misinformation Myth: The side effects of Myth: The COVID-19 Myth: If I’ve already had the COVID-19 vaccine are vaccine can affect COVID-19, I don’t need a dangerous. women’s fertility. vaccine. Myth: Researchers rushed the development of the Myth: Getting the COVID- Myth: The COVID-19 COVID-19 vaccine, so its 19 vaccine gives you vaccine can affect effectiveness and safety COVID-19. women’s fertility. cannot be trusted. Myth: The COVID-19 vaccine enters your cells and changes your DNA. Information gathered from the following website: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/covid-19-vaccines-myth-versus-fact https://www.muhealth.org/our-stories/covid-19-vaccine-myths-vs-facts FACT: People who have gotten sick with COVID-19 may still benefit from getting vaccinated. Due to the severe health risks associated with COVID-19 and the fact that re-infection with COVID-19 is possible, people may be advised to get a COVID-19 vaccine If I’ve already had even if they have been sick with COVID-19 before. There is not enough information currently available to COVID-19, I don’t say if or for how long people are protected from getting COVID-19 after they have had it (natural need a vaccine. immunity). Early evidence suggests natural immunity from COVID-19 may not last very long, but more studies are needed to better understand this. Several subjects in the Pfizer trial who were previously infected got vaccinated without ill effects. Some scientists believe the vaccine offers better protection for coronavirus than natural infection.
    [Show full text]
  • Proteasomes on the Chromosome Cell Research (2017) 27:602-603
    602 Cell Research (2017) 27:602-603. © 2017 IBCB, SIBS, CAS All rights reserved 1001-0602/17 $ 32.00 RESEARCH HIGHLIGHT www.nature.com/cr Proteasomes on the chromosome Cell Research (2017) 27:602-603. doi:10.1038/cr.2017.28; published online 7 March 2017 Targeted proteolysis plays an this process, both in mediating homolog ligases, respectively, as RN components important role in the execution and association and in providing crossovers that impact crossover formation [5, 6]. regulation of many cellular events. that tether homologs and ensure their In the first of the two papers, Ahuja et Two recent papers in Science identify accurate segregation. Meiotic recom- al. [7] report that budding yeast pre9∆ novel roles for proteasome-mediated bination is initiated by DNA double- mutants, which lack a nonessential proteolysis in homologous chromo- strand breaks (DSBs) at many sites proteasome subunit, display defects in some pairing, recombination, and along chromosomes, and the multiple meiotic DSB repair, in chromosome segregation during meiosis. interhomolog interactions formed by pairing and synapsis, and in crossover Protein degradation by the 26S pro- DSB repair drive homolog association, formation. Similar defects are seen, teasome drives a variety of processes culminating in the end-to-end homolog but to a lesser extent, in cells treated central to the cell cycle, growth, and dif- synapsis by a protein structure called with the proteasome inhibitor MG132. ferentiation. Proteins are targeted to the the synaptonemal complex (SC) [3]. These defects all can be ascribed to proteasome by covalently ligated chains SC-associated focal protein complexes, a failure to remove nonhomologous of ubiquitin, a small (8.5 kDa) protein.
    [Show full text]
  • Update on Approved and Candidate COVID-19 Vaccines in the EU
    Update on approved and candidate COVID-19 vaccines in the EU Dr. Marco Cavaleri Head of Biological Health Threats and Vaccines Strategy, EMA An agency of the European Union Outline 1 EMA response to COVID-19 pandemic - milestones 2 COVID-19 vaccines approved in the EU 3 Benefits and risks of COVID-19 vaccines 4 Real world evidence on effectiveness 5 Studies in children 6 Vaccines under review by EMA 7 Adapting COVID-19 vaccines to variants 8 Additional information Classified as public by the European Medicines Agency EMA RESPONSE TO COVID-19 PANDEMIC Milestones in the fight against the pandemic Scientific & regulatory Rapid development & Transparency & mobilisation evaluation outreach Approval: Comirnaty, COVID-19 vaccine Moderna, COVID-19 vaccine AstraZeneca, COVID-19 vaccine Janssen Accelerated development & evaluation procedures WHO declares pandemic COVID-19 Experts’ Task Force Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2020 2021 1 Classified as public by the European Medicines Agency COVID-19 vaccines approved in the EU 4 vaccines authorised in the EU • Comirnaty and Moderna vaccines contain a molecule called messenger RNA (mRNA) with instructions for producing the spike protein from SARS-CoV-2, the virus that causes COVID-19 • The AstraZeneca and Janssen vaccine uses a non-replicating adenovirus as a carrier that has been modified to produce the spike protein from SARS-CoV-2. • The vaccines do not contain the SARS-CoV-2 virus causing COVID-19 itself and cannot cause the disease. Comirnaty COVID-19 Vaccine COVID-19 Vaccine COVID-19 Vaccine (BioNTech/Pfizer) Moderna AstraZeneca Janssen 21 Dec 6 Jan 29 Jan 11 Mar 2 Classified as public by the European Medicines Agency BENEFITS AND RISKS Efficacy of COVID-19 vaccines in trials All COVID-19 vaccines approved in the EU have a positive benefit-risk balance in prevention of COVID-19 disease.
    [Show full text]
  • Documentation and Localization of Force-Mediated Filamin a Domain
    ARTICLE Received 29 May 2014 | Accepted 10 Jul 2014 | Published 14 Aug 2014 DOI: 10.1038/ncomms5656 Documentation and localization of force-mediated filamin A domain perturbations in moving cells Fumihiko Nakamura1, Mia Song1, John H. Hartwig1 & Thomas P. Stossel1 Endogenously and externally generated mechanical forces influence diverse cellular activities, a phenomenon defined as mechanotransduction. Deformation of protein domains by application of stress, previously documented to alter macromolecular interactions in vitro, could mediate these effects. We engineered a photon-emitting system responsive to unfolding of two repeat domains of the actin filament (F-actin) crosslinker protein filamin A (FLNA) that binds multiple partners involved in cell signalling reactions and validated the system using F-actin networks subjected to myosin-based contraction. Expressed in cultured cells, the sensor-containing FLNA construct reproducibly reported FLNA domain unfolding strikingly localized to dynamic, actively protruding, leading cell edges. The unfolding signal depends upon coherence of F-actin-FLNA networks and is enhanced by stimulating cell contractility. The results establish protein domain distortion as a bona fide mechanism for mechanotransduction in vivo. 1 Translational Medicine Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02445, USA. Correspondence and requests for materials should be addressed to F.N. (email: [email protected]). NATURE COMMUNICATIONS | 5:4656 | DOI: 10.1038/ncomms5656
    [Show full text]
  • Lipid-Targeting Pleckstrin Homology Domain Turns Its Autoinhibitory Face Toward the TEC Kinases
    Lipid-targeting pleckstrin homology domain turns its autoinhibitory face toward the TEC kinases Neha Amatyaa, Thomas E. Walesb, Annie Kwonc, Wayland Yeungc, Raji E. Josepha, D. Bruce Fultona, Natarajan Kannanc, John R. Engenb, and Amy H. Andreottia,1 aRoy J. Carver Department of Biochemistry, Biophysics and Molecular Biology, Iowa State University, Ames, IA 50011; bDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115; and cInstitute of Bioinformatics and Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA 30602 Edited by Natalie G. Ahn, University of Colorado Boulder, Boulder, CO, and approved September 17, 2019 (received for review May 3, 2019) The pleckstrin homology (PH) domain is well known for its phos- activation loop phosphorylation site are also controlled by noncatalytic pholipid targeting function. The PH-TEC homology (PHTH) domain domains (17). In addition to the N-terminal PHTH domain, the within the TEC family of tyrosine kinases is also a crucial component TEC kinases contain a proline-rich region (PRR) and Src ho- of the autoinhibitory apparatus. The autoinhibitory surface on the mology 3 (SH3) and Src homology 2 (SH2) domains that impinge PHTH domain has been previously defined, and biochemical investi- on the kinase domain to alter the conformational ensemble and gations have shown that PHTH-mediated inhibition is mutually thus the activation status of the enzyme. A crystal structure of the exclusive with phosphatidylinositol binding. Here we use hydrogen/ BTK SH3-SH2-kinase fragment has been solved (10) showing that deuterium exchange mass spectrometry, nuclear magnetic resonance the SH3 and SH2 domains of BTK assemble onto the distal side of (NMR), and evolutionary sequence comparisons to map where and the kinase domain (the surface opposite the activation loop), how the PHTH domain affects the Bruton’s tyrosine kinase (BTK) stabilizing the autoinhibited form of the kinase in a manner similar domain.
    [Show full text]
  • Multiple Recombination Events and Strong Purifying Selection at the Origin of SARS-Cov-2 Spike Glycoprotein Increased Correlated Dynamic Movements
    International Journal of Molecular Sciences Article Multiple Recombination Events and Strong Purifying Selection at the Origin of SARS-CoV-2 Spike Glycoprotein Increased Correlated Dynamic Movements Massimiliano S. Tagliamonte 1,2,† , Nabil Abid 3,4,†, Stefano Borocci 5,6 , Elisa Sangiovanni 5, David A. Ostrov 2 , Sergei L. Kosakovsky Pond 7, Marco Salemi 1,2,*, Giovanni Chillemi 5,8,*,‡ and Carla Mavian 1,2,*,‡ 1 Emerging Pathogen Institute, University of Florida, Gainesville, FL 32608, USA; mstagliamonte@ufl.edu 2 Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA; [email protected]fl.edu 3 Laboratory of Transmissible Diseases and Biological Active Substances LR99ES27, Faculty of Pharmacy, University of Monastir, Rue Ibn Sina, 5000 Monastir, Tunisia; [email protected] 4 Department of Biotechnology, High Institute of Biotechnology of Sidi Thabet, University of Manouba, BP-66, 2020 Ariana-Tunis, Tunisia 5 Department for Innovation in Biological, Agro-food and Forest Systems (DIBAF), University of Tuscia, via S. Camillo de Lellis s.n.c., 01100 Viterbo, Italy; [email protected] (S.B.); [email protected] (E.S.) 6 Institute for Biological Systems, National Research Council, Via Salaria, Km 29.500, 00015 Monterotondo, Rome, Italy 7 Department of Biology, Temple University, Philadelphia, PA 19122, USA; [email protected] 8 Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies (IBIOM), National Research Council, Via Giovanni Amendola, 122/O, 70126 Bari, Italy * Correspondence: [email protected]fl.edu (M.S.); [email protected] (G.C.); cmavian@ufl.edu (C.M.) † Authors contributed equally as first to this work. ‡ Authors contributed equally as last to this work.
    [Show full text]
  • Statements Contained in This Release As the Result of New Information Or Future Events Or Developments
    Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant NEW YORK and MAINZ, GERMANY, July 8, 2021 — As part of Pfizer’s and BioNTech’s continued efforts to stay ahead of the virus causing COVID-19 and circulating mutations, the companies are providing an update on their comprehensive booster strategy. Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two primary doses. The companies expect to publish more definitive data soon as well as in a peer-reviewed journal and plan to submit the data to the FDA, EMA and other regulatory authorities in the coming weeks. In addition, data from a recent Nature paper demonstrate that immune sera obtained shortly after dose 2 of the primary two dose series of BNT162b2 have strong neutralization titers against the Delta variant (B.1.617.2 lineage) in laboratory tests. The companies anticipate that a third dose will boost those antibody titers even higher, similar to how the third dose performs for the Beta variant (B.1.351). Pfizer and BioNTech are conducting preclinical and clinical tests to confirm this hypothesis. While Pfizer and BioNTech believe a third dose of BNT162b2 has the potential to preserve the highest levels of protective efficacy against all currently known variants including Delta, the companies are remaining vigilant and are developing an updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant.
    [Show full text]